{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T08:09:03Z","timestamp":1777622943066,"version":"3.51.4"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.trim.2017.12.004","type":"journal-article","created":{"date-parts":[[2017,12,23]],"date-time":"2017-12-23T14:17:42Z","timestamp":1514038662000},"page":"10-17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival"],"prefix":"10.1016","volume":"47","author":[{"given":"Justa","family":"Friebus-Kardash","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deniz","family":"Keles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Heinold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Kribben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko Markus","family":"Heinemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ute","family":"Eisenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5425","key":"10.1016\/j.trim.2017.12.004_bb0005","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1126\/science.285.5425.260","article-title":"BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator","volume":"285","author":"Moore","year":"1999","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.trim.2017.12.004_bb0010","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cytogfr.2013.04.003","article-title":"The BAFF\/APRIL system: emerging functions beyond B cell biology and autoimmunity","volume":"24","author":"Vincent","year":"2013","journal-title":"Cytokine Growth Factor Rev."},{"issue":"3","key":"10.1016\/j.trim.2017.12.004_bb0015","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.clim.2012.11.010","article-title":"Targeting the BLyS-APRIL signaling pathway in SLE","volume":"148","author":"La Cava","year":"2013","journal-title":"Clin. Immunol."},{"issue":"12","key":"10.1016\/j.trim.2017.12.004_bb0020","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1002\/art.11354","article-title":"B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations","volume":"48","author":"Stohl","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.trim.2017.12.004_bb0025","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/1529-0131(200106)44:6<1313::AID-ART223>3.0.CO;2-S","article-title":"Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases","volume":"44","author":"Cheema","year":"2001","journal-title":"Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.trim.2017.12.004_bb0030","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sj\u00f6gren's syndrome","volume":"109","author":"Groomv","year":"2002","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.trim.2017.12.004_bb0035","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/tri.12217","article-title":"Factors influencing long-term outcome after kidney transplantation","volume":"27","author":"Legendre","year":"2014","journal-title":"Transpl. Int."},{"issue":"12","key":"10.1016\/j.trim.2017.12.004_bb0040","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation","volume":"8","author":"Bruns","year":"2008","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.trim.2017.12.004_bb0045","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/phar.1426","article-title":"Antibody-mediated rejection in kidney transplantation: a review of pathophysiology, diagnosis, and treatment options","volume":"34","author":"Kim","year":"2014","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.trim.2017.12.004_bb0050","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrneph.2012.61","article-title":"Diagnostic challenges in chronic antibody-mediated rejection","volume":"8","author":"Farkash","year":"2012","journal-title":"Nat. Rev. Nephrol."},{"issue":"9","key":"10.1016\/j.trim.2017.12.004_bb0055","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1097\/01.TP.0000438211.34842.5e","article-title":"Peripheral B-cell phenotype and BAFF are associated with HLA immunization in patients awaiting kidney transplantation","volume":"97","author":"Snanoudj","year":"2014","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.trim.2017.12.004_bb0060","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/TP.0b013e318298dd65","article-title":"Elevated pretransplantation soluble BAFF is associated with an increased risk of acute antibody-mediated rejection","volume":"96","author":"Banham","year":"2013","journal-title":"Transplantation"},{"issue":"10","key":"10.1016\/j.trim.2017.12.004_bb0065","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1111\/j.1600-6143.2012.04194.x","article-title":"BAFF and BAFF-R levels are associated with risk of long-term kidney graft dysfunction and development of donor-specific antibodies","volume":"12","author":"Thibault-Espitia","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2017.12.004_bb0070","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.transproceed.2008.10.037","article-title":"The expression of B-cell activating factor belonging to tumor necrosis factor superfamily (BAFF) significantly correlated with C4d in kidney allograft rejection","volume":"41","author":"Xu","year":"2009","journal-title":"Transplant. Proc."},{"issue":"2","key":"10.1016\/j.trim.2017.12.004_bb0075","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/ki.2012.395","article-title":"The Banff classification revisited","volume":"83","author":"Solez","year":"2013","journal-title":"Kidney Int."},{"key":"10.1016\/j.trim.2017.12.004_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.5414\/CNP75271","article-title":"C4d-negative antibody-mediated rejection in renal allografts: evidence for its existence and effect on graft survival","volume":"75","author":"Haas","year":"2011","journal-title":"Clin. Nephrol."},{"issue":"14","key":"10.1016\/j.trim.2017.12.004_bb0085","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1056\/NEJM196904032801401","article-title":"Significance of the positive crossmatch test in kidney transplantation","volume":"280","author":"Patel","year":"1969","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.trim.2017.12.004_bb0090","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.humimm.2010.05.001","article-title":"High negative predictive value of an amplified flow cytometry crossmatch before living donor kidney transplantation","volume":"71","author":"Lindemann","year":"2010","journal-title":"Hum. Immunol."},{"issue":"4","key":"10.1016\/j.trim.2017.12.004_bb0095","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1159\/000228834","article-title":"HLA genotyping and antibody characterization using the Luminex multiplex technology","volume":"36","author":"Heinemann","year":"2009","journal-title":"Transfus. Med. Hemother."},{"issue":"1","key":"10.1016\/j.trim.2017.12.004_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/TP.0b013e31827a19cc","article-title":"Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation","volume":"95","author":"Tait","year":"2013","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.trim.2017.12.004_bb0105","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1084\/jem.190.11.1697","article-title":"Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations","volume":"190","author":"Mackay","year":"1999","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.trim.2017.12.004_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/ndt\/gfu213","article-title":"'That obscure object of desire ': in systemic lupus erythematosus B-cell activating factor\/B-lymphocyte stimulator is targeted both by the immune system and by physicians","volume":"30","author":"Sanchez-Ni\u00f1o","year":"2014","journal-title":"Nephrol. Dial. Transplant."},{"issue":"20","key":"10.1016\/j.trim.2017.12.004_bb0115","doi-asserted-by":"crossref","first-page":"6107","DOI":"10.1158\/1078-0432.CCR-07-1290","article-title":"High levels of B-cell activating factor in patients with active chronic graft-versus-host disease","volume":"13","author":"Sarantopoulos","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.trim.2017.12.004_bb0120","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1097\/TP.0b013e3181735723","article-title":"B cell survival in intragraft tertiary lymphoid organs after rituximab therapy","volume":"85","author":"Thaunat","year":"2008","journal-title":"Transplantation"},{"issue":"41","key":"10.1016\/j.trim.2017.12.004_bb0125","doi-asserted-by":"crossref","first-page":"14723","DOI":"10.1073\/pnas.0507223102","article-title":"Lymphoid neogenesis in chronic rejection: evidence for a local humoral alloimmune response","volume":"102","author":"Thaunat","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6","key":"10.1016\/j.trim.2017.12.004_bb0130","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011398","article-title":"Immune responses elicited in tertiary lymphoid tissues display distinctive features","volume":"5","author":"Thaunat","year":"2010","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.trim.2017.12.004_bb0135","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1016\/j.transproceed.2016.09.019","article-title":"B-cell-activating factor levels are associated with antibody-mediated histological damage in kidney transplantation","volume":"48","author":"Sangoa","year":"2016","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2017.12.004_bb0140","article-title":"B-cell activating factor (BAFF), a predictor of antibody mediated rejection in kidney transplantation recipients","author":"Pongpirul","year":"2016","journal-title":"Nephrology (Carlton)"},{"key":"10.1016\/j.trim.2017.12.004_bb0145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0162964","article-title":"Clinical significance of pre- and post-transplant BAFF levels in kidney transplant recipients","volume":"11","author":"Min","year":"2016","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.trim.2017.12.004_bb0150","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1600-6143.2004.00360.x","article-title":"Predicting kidney graft failure by HLA antibodies: a prospective trial","volume":"4","author":"Terasaki","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2017.12.004_bb0155","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1097\/01.tp.0000174338.97313.5a","article-title":"Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2-year prospective trial","volume":"80","author":"Terasaki","year":"2005","journal-title":"Transplantation"},{"issue":"11","key":"10.1016\/j.trim.2017.12.004_bb0160","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1097\/TP.0b013e3181a5e034","article-title":"Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads","volume":"87","author":"Amico","year":"2009","journal-title":"Transplantation"},{"issue":"7","key":"10.1016\/j.trim.2017.12.004_bb0165","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2013-002852","article-title":"Belimumab: a technological advance for systemic lupus erythematosus patients? Report of a systematic review and meta-analysis","volume":"3","author":"Kandala","year":"2013","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.trim.2017.12.004_bb0170","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/ajt.13045","article-title":"Neutralizing BAFF\/APRIL with atacicept prevents early DSA formation and AMR development in T cell depletion induced nonhuman primate AMR model","volume":"15","author":"Kwun","year":"2015","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2017.12.004_bb0175","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/ajt.13557","article-title":"Effect of treatment with tabalumab, a B cell-activating factor inhibitor, on highly sensitized patients with end-stage renal disease awaiting transplantation","volume":"16","author":"Mujtaba","year":"2016","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2017.12.004_bb0180","series-title":"18th Congress of the European Society for Organ Transplantation (ESOT) in Barcelona","article-title":"A phase-two, randomised, placebo-controlled trial of belimumab in renal transplantation suggests de novo antibody formation is reduced in belimumab treated patients","author":"Flint","year":"2017"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327417301739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327417301739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,14]],"date-time":"2018-08-14T02:12:40Z","timestamp":1534212760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327417301739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":36,"alternative-id":["S0966327417301739"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2017.12.004","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2017.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}